Atb Cap Markets Has Positive View of Organigram Q3 Earnings

Organigram Holdings Inc. (TSE:OGI) – Atb Cap Markets increased their Q3 2025 earnings per share estimates for shares of Organigram in a report issued on Monday, May 12th. Atb Cap Markets analyst F. Gomes now forecasts that the company will post earnings of ($0.02) per share for the quarter, up from their previous forecast of ($0.03). The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram’s Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at $0.10 EPS, FY2026 earnings at $0.02 EPS, FY2027 earnings at $0.11 EPS and FY2028 earnings at $0.15 EPS.

Organigram Stock Performance

Shares of OGI stock opened at C$1.73 on Thursday. The stock has a market capitalization of C$213.73 million, a PE ratio of -3.66, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. Organigram has a 52-week low of C$1.22 and a 52-week high of C$2.87. The stock’s 50-day moving average price is C$1.50 and its 200 day moving average price is C$1.91. The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07.

About Organigram

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.